NIH-funded research U01 cooperative agreement

Gut–brain connections in Parkinson's disease

Official title: The Bidirectional Gut-Microbiota-Brain Axis in Parkinson’s disease: integrating mechanistic biomarkers of disease severity and progression

Funded at Rush University Medical Center · NIH-11362899 · Data updated 2026-11-12

This project adds gut and brain tests to look for gut-based signs that track Parkinson's disease progression in people living with Parkinson's.

Quick facts

Grant typeU01 cooperative agreement
Study typeNIH-funded research
Funding institutionRush University Medical Center
NIH-funded
Lab location1 site (Chicago, United States)
Project startAugust 15, 2024
Project endJune 30, 2029
Funding year2025
Award (this year)$214,082
NIH project number3U01DK140923-02S1
Project IDNIH-11362899 on NIH RePORTER

Who could benefit from this research

Could help

People diagnosed with Parkinson's disease who can visit a consortium clinic and are willing to provide stool and skin samples and undergo gastrointestinal and swallowing tests would be ideal candidates.

Less likely to help

People without Parkinson's, those unable to travel to participating centers, or those who cannot undergo biopsies or GI testing are unlikely to benefit directly from this project.

What this research studies

This supplement adds extra gastrointestinal and neurological tests to the existing consortium work to better link gut changes with Parkinson's symptoms. You may be asked to provide stool samples and skin biopsies and to undergo tests such as videofluoroscopic swallowing, anorectal manometry with balloon expulsion, and measurements of intestinal transit time. Specialized laboratory analyses will examine the microbiome using culturomics and metabolomics and will measure intestinal barrier integrity. Rush and partner centers will analyze samples from about 200 additional consortium participants to search for gut-based biomarkers tied to disease severity and progression.

Why it matters

Potential benefit: If successful, the work could lead to new gut-based biomarkers and targets that help diagnose, monitor, or eventually treat Parkinson's disease more effectively.

How similar studies have gone: Previous studies have suggested links between the gut microbiome and Parkinson's, but translating these findings into reliable clinical biomarkers remains largely unproven.

Where this research is happening

  • Rush University Medical Center
    Chicago, United States
    Active

Researchers

  • Principal investigator: Keshavarzian, Ali — Rush University Medical Center
  • Study coordinator: Keshavarzian, Ali

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.